Jump to content

Paxlovid COVID Pills Have No Benefit for Adults 40-65, Study Shows


Danderman123

Recommended Posts

Be fair in reporting the full results of the cited study, per the original source of your OP news report:

 

"The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection. That's consistent with earlier results used to authorize the drug in the U.S. and other nations."

 

AND

 

"The study has limitations due to its design, which compiled data from a large Israeli health system rather than enrolling patients in a randomized study with a control group — the gold standard for medical research."

 

https://www.usatoday.com/story/news/health/2022/08/24/paxlovid-pfizer-covid-pill-benefits-adults/7889907001/

 

It's not a perfect medication. But it's not a useless one either.

 

Edited by TallGuyJohninBKK
  • Like 1
Link to comment
Share on other sites

It does have benefit for people under age 65 who have other risk factors.

 

The clinical trials were unable to show a benefit in people under 65 with no special risk factors because the outcome being measured (need for hospitalization) was already so infrequent even in the control group. 

 

This has all been known from the start.

 

Relapse is rare.

  • Like 1
Link to comment
Share on other sites

1 hour ago, Danderman123 said:

 

Nothing in that address the frequency of rebound. Rather it discussed the significance of rebound (little to none) and indications for its management (no need to to retreat).

 

Incidence of rebound after Paxlovid is low.  1-2% in some studies, 3-5% in others. Nowhere has the CDC or anyone else said it is common or usual, far from it.

  • Like 1
Link to comment
Share on other sites

7 minutes ago, Sheryl said:

 

Nothing in that address the frequency of rebound. Rather it discussed the significance of rebound (little to none) and indications for its management (no need to to retreat).

 

Incidence of rebound after Paxlovid is low.  1-2% in some studies, 3-5% in others. Nowhere has the CDC or anyone else said it is common or usual, far from it.

I recently watched FoxNews and their take on Paxlovid was that because of the anecdotal evidence of both Biden and wife getting rebound, the CDC recommendation was a "joke". This seems to be in line with their usual COVID narrative.

Link to comment
Share on other sites

51 minutes ago, Sheryl said:

 

Nothing in that address the frequency of rebound. Rather it discussed the significance of rebound (little to none) and indications for its management (no need to to retreat).

 

Incidence of rebound after Paxlovid is low.  1-2% in some studies, 3-5% in others. Nowhere has the CDC or anyone else said it is common or usual, far from it.

https://www.nature.com/articles/d41586-022-02121-z
 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258292/

Link to comment
Share on other sites

4 hours ago, Danderman123 said:

The upshot of your above cited study:

 

"Conclusions and Relevance COVID-19 rebound occurred both after Paxlovid and Molnupiravir, especially in patients with underlying medical conditions. This indicates that COVID-19 rebound is not unique to Paxlovid and the risks were similar for Paxlovid and Molnupiravir. For both drugs the rates of COVID-19 rebound increased with time after treatments."

 

 

  • Like 1
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.




  • Popular Now

×
×
  • Create New...